About This Program
This program aims to develop anti-Galectin-3 therapeutic monoclonal antibody for non-small cell lung cancer immunotherapy.
Rationale for our program:
Advanced non-small cell lung cancer (NSCLC) cannot be cured, with a median survival of 12 months. There is an urgent need for more effective treatments.
Immunotherapy (e.g. anti-PD-L1, PD-1, and CTLA-4) has recently been shown unprecedented efficacy in patients with NSCLC. However, the patient's response is limited, thus promoting an intensive study that combines immune checkpoint inhibition with other targeted drugs to overcome resistance.
Galectin-3 is highly expressed in the tumor microenvironment of invasive cancers, and its expression is associated with poor survival, particularly in patients with NSCLC. Numerous studies have revealed the inhibitory effect of galectin-3 on activated cytotoxic T lymphocyte CTLs and are critical for M2 macrophage differentiation.
Given the above, Galectin-3 is an ideal candidate target for the treatment of NSCLC.
Full Article: Next-IO™ Anti-Galectin-3 Therapeutic Monoclonal Antibody Program
Add comment
Comments